TRIGENESIS
DEAD

Serial Number

88811637

Owner

SAREPTA THERAPEUTICS, INC.

Attorney

Paul C. Llewellyn

Filing Date

Feb 26, 2020

Add to watchlist:

No watchlists yet
View on USPTO

TRIGENESIS Trademark

Serial Number: 88811637

TRIGENESIS is a trademark filed by SAREPTA THERAPEUTICS, INC. on February 26, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 16 (Paper Goods). The application is currently no longer active.

Owner Contact Info

SAREPTA THERAPEUTICS, INC. (109 trademarks)

215 FIRST STREET, SUITE 7
CAMBRIDGE, MA 02142

Entity Type: 03

Trademark Details

Filing Date

February 26, 2020

Registration Date

Not Registered

Published for Opposition

April 21, 2020

Goods & Services

Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform; Pharmaceutical preparations that modulate RNA expression; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapies for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products for the treatment of genetic disorders and diseases

Printed materials, namely, brochures, leaflets, reports, and newsletters on the topics of medicine, medical research, scientific research, research and development of pharmaceuticals, biological preparations and gene therapy products, rare and infectious diseases, neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, genetic therapy research, and diagnosis and treatment of genetic disorders

Medical information services, namely, providing information relating to of medicine, medical research, scientific research, research and development of pharmaceuticals, biological preparations and gene therapy products, rare and infectious diseases, neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, genetic therapy research, and diagnosis and treatment of genetic disorders; Providing a website and information in the field of medicine, medical research, scientific research, research and development of pharmaceuticals, biological preparations and gene therapy products, rare and infectious diseases, neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, genetic therapy research, and diagnosis and treatment of genetic disorders; Provision of health care services, namely, providing information to doctors and patients regarding rare diseases, medicines, health conditions and treatment options

Medical research; medical and scientific research services all in the field of rare and infectious diseases; medical and scientific research services all in the field of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, and genetic diseases and disorders; medical and scientific research services all in the field of gene therapy, gene editing, genome editing, viruses, viral vectors, and viral constructs

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jan 17, 2023 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jan 16, 2023 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 15, 2022 EXRA
SOU EXTENSION 4 GRANTED
Jun 13, 2022 EX4G
SOU EXTENSION 4 FILED
Jun 13, 2022 EXT4
SOU TEAS EXTENSION RECEIVED
Jun 13, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 4, 2021 EXRA
SOU EXTENSION 3 GRANTED
Dec 2, 2021 EX3G
SOU EXTENSION 3 FILED
Dec 2, 2021 EXT3
SOU TEAS EXTENSION RECEIVED
Dec 2, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 20, 2021 EXRA
SOU EXTENSION 2 GRANTED
May 18, 2021 EX2G
SOU EXTENSION 2 FILED
May 18, 2021 EXT2
SOU TEAS EXTENSION RECEIVED
May 18, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 10, 2020 EXRA
SOU EXTENSION 1 GRANTED
Dec 8, 2020 EX1G
SOU EXTENSION 1 FILED
Dec 8, 2020 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 8, 2020 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 16, 2020 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 21, 2020 NPUB
PUBLISHED FOR OPPOSITION
Apr 21, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 1, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 13, 2020 CNSA
ASSIGNED TO EXAMINER
Mar 13, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 6, 2020 NWOS
NEW APPLICATION ENTERED
Mar 5, 2020 NWAP